Information regarding Lung Cancer Treatment

The request was successful.

Dear Gloucestershire Health and Care NHS Foundation Trust,

I would like to ask the following question regarding lung cancer treatment.

The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many metastatic non-small cell lung cancer (NSCLC) patients were treated with any of the following:

• Afatinib
• Alectinib
• Atezolizumab monotherapy
• Atezolizumab in combination
• Bevacizumab
• Brigatinib
• Capmatenib
• Ceritinib
• Crizotinib
• Dacomitinib
• Dabrafenib with Trametinib
• Docetaxel monotherapy
• Durvalumab
• Erlotinib
• Gefitinib
• Gemcitabine
• Nintedanib with Docetaxel
• Nivolumab
• Osimertinib
• Paclitaxel
• Pembrolizumab monotherapy
• Pembrolizumab in combination
• Pemetrexed with Carboplatin/Cisplatin
• Tepotinib
• Vinorelbine with Cisplatin/Carboplatin
• Any other SACT
• Palliative care only

Thank you for taking the time to answer this question and I look forward to hearing from you.

Yours faithfully,

David Elder

Freedom of Information, Gloucestershire Health and Care NHS Foundation Trust

Dear David,

Thank you for your freedom of information request below.

Unfortunately this does not relate to Gloucestershire Health & Care NHS Foundation Trust.

Can we therefore suggest that you contact Gloucestershire Hospital NHS Foundation Trust who should be able to provide this information.

https://www.gloshospitals.nhs.uk/about-u...

Many thanks,

Danielle Simons
Legal Services Officer (Legal Services)
Gloucestershire Health and Care NHS Foundation Trust
Address: Edward Jenner Court, Pioneer Avenue, Gloucester Business Park, Brockworth, GL3 4AW
Telephone: 0300 421 8357  Email: [email address]   Website: www.ghc.nhs.uk

show quoted sections